Abstract
OBJECTIVE: To evaluate the effects of tinidazole (TNZ) combined with minocycline (MINO) on therapeutic effectiveness, bone resorption, and inflammation in peri-implantitis (PI). METHODS: This retrospective study included 96 PI patients admitted between January 2023 and February 2024. Patients were divided into a control group (n = 46) treated with MINO and a research group (n = 50) treated with TNZ plus MINO. Therapeutic effectiveness, post-treatment plaque biofilm activity at different depths, periodontal indexes [modified plaque index (mPLI), modified sulcus bleeding index (mSBI), probing depth (PD), and peri-implant marginal bone loss (MBL)], inflammatory markers [interleukin (IL)-1β, IL-8, and matrix metalloproteinase-8 (MMP-8)], pain scores [Visual Analogue Scale (VAS)], quality of life [Short Form 36 Item Health Survey (SF-36)], and adverse reactions were compared. Univariate and multivariate analyses were performed to identify factors influencing therapeutic effectiveness. RESULTS: The research group demonstrated significantly higher therapeutic effectiveness and lower mPLI, mSBI, PD, MBL, and plaque biofilm activity at different depths compared to the control group (all P < 0.05). Additionally, greater reductions in VAS scores and increases in SF-36 scores were observed in the research group post-treatment (both P < 0.05). No severe adverse reactions occurred in either group, and the incidence of adverse events showed no significant inter-group difference (P > 0.05). Univariate analysis revealed that disease duration, history of periodontitis, smoking, and treatment modality were significantly associated with therapeutic effectiveness (all P < 0.05). Multivariate analysis identified smoking as an independent factor influencing treatment outcome. CONCLUSIONS: TNZ combined with MINO is a highly effective and safe treatment for PI. This combination reduces plaque, alleviates periodontitis, and improves patients' quality of life.